- Home
- PANW vs NVS Comparison
PANW vs NVS Comparison
Compare PANW & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PANW | NVS |
|---|---|---|
| Founded | 2005 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | 75267 |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.3B | 286.5B |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | PANW | NVS |
|---|---|---|
| Price | $284.40 | $151.37 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 39 | 5 |
| Target Price | ★ $216.28 | $144.00 |
| AVG Volume (30 Days) | ★ 8.5M | 1.6M |
| Earning Date | 05-19-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 2.16% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $2,273,100,000.00 | N/A |
| Revenue This Year | $24.93 | $2.30 |
| Revenue Next Year | $19.97 | $5.27 |
| P/E Ratio | $359.49 | ★ $23.13 |
| Revenue Growth | ★ 29.04 | N/A |
| 52 Week Low | $139.57 | $112.34 |
| 52 Week High | $302.95 | $170.46 |
Technical Indicators
Market Signals| Indicator | PANW | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 66.25 | 54.55 |
| Support Level | $179.81 | $149.49 |
| Resistance Level | $302.95 | $152.55 |
| Average True Range (ATR) | 13.79 | 2.05 |
| MACD | -2.43 | 0.54 |
| Stochastic Oscillator | 66.70 | 74.94 |
Price Performance
Historical ComparisonAbout PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three-fourths of the Global 2000.
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.